| node1 | node2 | node1 accession | node2 accession | node1 annotation | node2 annotation | score |
| OGFR | OGFRL1 | ENSSSCP00000047156 | ENSSSCP00000059160 | Opioid growth factor receptor. | Opioid growth factor receptor like 1. | 0.907 |
| OGFR | OPRD1 | ENSSSCP00000047156 | ENSSSCP00000024665 | Opioid growth factor receptor. | Delta-type opioid receptor; G-protein coupled receptor that functions as receptor for endogenous enkephalins and for a subset of other opioids. Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates the activity of down-stream effectors, such as adenylate cyclase. Signaling leads to the inhibition of adenylate cyclase activity. Inhibits neurotransmitter release by reducing calcium ion currents and increasing potassium ion conductance. Plays a role in the perception of pain and in opiate-mediated analgesia. [...] | 0.919 |
| OGFR | OPRK1 | ENSSSCP00000047156 | ENSSSCP00000006677 | Opioid growth factor receptor. | Opioid receptor kappa 1; Belongs to the G-protein coupled receptor 1 family. | 0.919 |
| OGFR | OPRL1 | ENSSSCP00000047156 | ENSSSCP00000033028 | Opioid growth factor receptor. | Nociceptin receptor; G-protein coupled opioid receptor that functions as receptor for the endogenous neuropeptide nociceptin. Ligand binding causes a conformation change that triggers signaling via guanine nucleotide- binding proteins (G proteins) and modulates the activity of down-stream effectors. Signaling via G proteins mediates inhibition of adenylate cyclase activity and calcium channel activity. Arrestins modulate signaling via G proteins and mediate the activation of alternative signaling pathways that lead to the activation of MAP kinases. Plays a role in modulating nociceptio [...] | 0.919 |
| OGFR | OPRM1 | ENSSSCP00000047156 | ENSSSCP00000004401 | Opioid growth factor receptor. | Mu-type opioid receptor; Receptor for endogenous opioids such as beta-endorphin and endomorphin. Receptor for natural and synthetic opioids including morphine, heroin, DAMGO, fentanyl, etorphine, buprenorphin and methadone. Agonist binding to the receptor induces coupling to an inactive GDP-bound heterotrimeric G-protein complex and subsequent exchange of GDP for GTP in the G-protein alpha subunit leading to dissociation of the G-protein complex with the free GTP-bound G-protein alpha and the G-protein beta-gamma dimer activating downstream cellular effectors. The agonist- and cell typ [...] | 0.919 |
| OGFR | PDYN | ENSSSCP00000047156 | ENSSSCP00000031176 | Opioid growth factor receptor. | Alpha-neoendorphin; Leu-enkephalins compete with and mimic the effects of opiate drugs. They play a role in a number of physiologic functions, including pain perception and responses to stress (By similarity). Leumorphin has a typical opiod activity and may have anti- apoptotic effect. | 0.919 |
| OGFR | PENK | ENSSSCP00000047156 | ENSSSCP00000006655 | Opioid growth factor receptor. | Proenkephalin. | 0.938 |
| OGFR | PNOC | ENSSSCP00000047156 | ENSSSCP00000055008 | Opioid growth factor receptor. | Nociceptin. | 0.919 |
| OGFR | POMC | ENSSSCP00000047156 | ENSSSCP00000024582 | Opioid growth factor receptor. | Corticotropin-like intermediary peptide; [Corticotropin]: Stimulates the adrenal glands to release cortisol. [Melanocyte-stimulating hormone beta]: Increases the pigmentation of skin by increasing melanin production in melanocytes. [Met-enkephalin]: Endogenous opiate; Belongs to the POMC family. | 0.468 |
| OGFRL1 | OGFR | ENSSSCP00000059160 | ENSSSCP00000047156 | Opioid growth factor receptor like 1. | Opioid growth factor receptor. | 0.907 |
| OGFRL1 | OPRD1 | ENSSSCP00000059160 | ENSSSCP00000024665 | Opioid growth factor receptor like 1. | Delta-type opioid receptor; G-protein coupled receptor that functions as receptor for endogenous enkephalins and for a subset of other opioids. Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates the activity of down-stream effectors, such as adenylate cyclase. Signaling leads to the inhibition of adenylate cyclase activity. Inhibits neurotransmitter release by reducing calcium ion currents and increasing potassium ion conductance. Plays a role in the perception of pain and in opiate-mediated analgesia. [...] | 0.871 |
| OGFRL1 | OPRK1 | ENSSSCP00000059160 | ENSSSCP00000006677 | Opioid growth factor receptor like 1. | Opioid receptor kappa 1; Belongs to the G-protein coupled receptor 1 family. | 0.871 |
| OGFRL1 | OPRL1 | ENSSSCP00000059160 | ENSSSCP00000033028 | Opioid growth factor receptor like 1. | Nociceptin receptor; G-protein coupled opioid receptor that functions as receptor for the endogenous neuropeptide nociceptin. Ligand binding causes a conformation change that triggers signaling via guanine nucleotide- binding proteins (G proteins) and modulates the activity of down-stream effectors. Signaling via G proteins mediates inhibition of adenylate cyclase activity and calcium channel activity. Arrestins modulate signaling via G proteins and mediate the activation of alternative signaling pathways that lead to the activation of MAP kinases. Plays a role in modulating nociceptio [...] | 0.871 |
| OGFRL1 | OPRM1 | ENSSSCP00000059160 | ENSSSCP00000004401 | Opioid growth factor receptor like 1. | Mu-type opioid receptor; Receptor for endogenous opioids such as beta-endorphin and endomorphin. Receptor for natural and synthetic opioids including morphine, heroin, DAMGO, fentanyl, etorphine, buprenorphin and methadone. Agonist binding to the receptor induces coupling to an inactive GDP-bound heterotrimeric G-protein complex and subsequent exchange of GDP for GTP in the G-protein alpha subunit leading to dissociation of the G-protein complex with the free GTP-bound G-protein alpha and the G-protein beta-gamma dimer activating downstream cellular effectors. The agonist- and cell typ [...] | 0.871 |
| OGFRL1 | PDYN | ENSSSCP00000059160 | ENSSSCP00000031176 | Opioid growth factor receptor like 1. | Alpha-neoendorphin; Leu-enkephalins compete with and mimic the effects of opiate drugs. They play a role in a number of physiologic functions, including pain perception and responses to stress (By similarity). Leumorphin has a typical opiod activity and may have anti- apoptotic effect. | 0.871 |
| OGFRL1 | PENK | ENSSSCP00000059160 | ENSSSCP00000006655 | Opioid growth factor receptor like 1. | Proenkephalin. | 0.885 |
| OGFRL1 | PNOC | ENSSSCP00000059160 | ENSSSCP00000055008 | Opioid growth factor receptor like 1. | Nociceptin. | 0.868 |
| OGFRL1 | POMC | ENSSSCP00000059160 | ENSSSCP00000024582 | Opioid growth factor receptor like 1. | Corticotropin-like intermediary peptide; [Corticotropin]: Stimulates the adrenal glands to release cortisol. [Melanocyte-stimulating hormone beta]: Increases the pigmentation of skin by increasing melanin production in melanocytes. [Met-enkephalin]: Endogenous opiate; Belongs to the POMC family. | 0.466 |
| OPRD1 | OGFR | ENSSSCP00000024665 | ENSSSCP00000047156 | Delta-type opioid receptor; G-protein coupled receptor that functions as receptor for endogenous enkephalins and for a subset of other opioids. Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates the activity of down-stream effectors, such as adenylate cyclase. Signaling leads to the inhibition of adenylate cyclase activity. Inhibits neurotransmitter release by reducing calcium ion currents and increasing potassium ion conductance. Plays a role in the perception of pain and in opiate-mediated analgesia. [...] | Opioid growth factor receptor. | 0.919 |
| OPRD1 | OGFRL1 | ENSSSCP00000024665 | ENSSSCP00000059160 | Delta-type opioid receptor; G-protein coupled receptor that functions as receptor for endogenous enkephalins and for a subset of other opioids. Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates the activity of down-stream effectors, such as adenylate cyclase. Signaling leads to the inhibition of adenylate cyclase activity. Inhibits neurotransmitter release by reducing calcium ion currents and increasing potassium ion conductance. Plays a role in the perception of pain and in opiate-mediated analgesia. [...] | Opioid growth factor receptor like 1. | 0.871 |
